defactinib: Clinical Trials

28 trials of defactinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 recruiting, 7 active not recruiting, 4 terminated, 3 completed. 28 Phase 2, 8 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 228Recruiting 10, Active not recruiting 7, Terminated 4, Completed 3, Not yet recruiting 3, Unknown 1
Phase 18Recruiting 3, Active not recruiting 2, Not yet recruiting 1, Terminated 1, Unknown 1

Follow defactinib: new trials by email Literature Review of defactinib trials Research Report on defactinib

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor
avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor)
Phase 2Not yet recruitingGirish Dhall, MD252027-01-012026-10-28
Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma
Avutometinib (VS-6766) + Defactinib (VS-6063) - Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2Not yet recruitingUniversity of Virginia312026-10-012026-09-17
Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
avutometinib + defactininb combination - Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Phase 2Not yet recruitingVerastem, Inc.22026-08-032026-08-05
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
Stereotactic body radiotherapy, Defactinib, Avutometinib - Pancreatic Adenocarcinoma, Cancer of the Pancreas
Phase 2RecruitingWashington University School of Medicine362026-04-102026-04-15
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab - Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingVerastem, Inc.6162025-06-242026-11-10
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Defactinib, Cetuximab, Avutometinib - Advanced Colorectal Cancer
Phase 2RecruitingM.D. Anderson Cancer Center332025-02-242026-09-25
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Avutometinib, Defactinib, Temozolomide - Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma)
Phase 1 / Phase 2RecruitingInstitute of Cancer Research, United Kingdom1822024-11-152026-01-21
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
Avutometinib (VS-6766) + Defactinib (VS-6063) - Low Grade Serous Ovarian Cancer, Ovarian Cancer
Phase 2Active not recruitingVerastem, Inc.162024-10-302025-12-17
Avutometinib and Defactinib in Diffuse Gastric Cancer
Avutometinib, Defactinib - Gastric Cancer, Stomach Cancer
Phase 2RecruitingRyan H. Moy, MD, PhD272024-10-282026-11-06
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Avutometinib, Biopsy, Biospecimen Collection - Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma
Phase 2RecruitingEmory University502024-07-312026-04-06
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Avutometinib, Defactinib, Letrozole - Low-Grade Serous Ovarian Cancer
Phase 2RecruitingMemorial Sloan Kettering Cancer Center202024-04-292026-10-23
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
Defactinib, Avutometinib, Encorafenib - Cutaneous Melanoma, Brain Metastases
Phase 1 / Phase 2RecruitingUniversity of Utah332024-03-202025-12-03
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Avutometinib, Defactinib - Thyroid Cancer
Phase 2RecruitingMemorial Sloan Kettering Cancer Center302023-08-162026-10-15
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel - KRAS Activating Mutation, Metastatic Cancer
Phase 1 / Phase 2Active not recruitingVerastem, Inc.402023-03-222025-09-02
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Avutometinib (VS-6766), Defactinib - Mesonephric Gynecologic Cancer
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center402023-03-152026-10-08
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Avutometinib (VS-6766) + defactinib - Endometrioid Cancer, Mucinous Ovarian Cancer
Phase 2RecruitingUniversity of Oklahoma552023-02-062025-10-22
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
avutometinib and sotorasib, avutometinib and sotorasib and defactinib - Non Small Cell Lung Cancer, KRAS Activating Mutation
Phase 1 / Phase 2Active not recruitingVerastem, Inc.1532022-04-122026-01-12
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Adaptive stereotactic body radiation therapy, Defactinib, Tumor biopsy - Pancreas Cancer, Cancer of the Pancreas
Phase 2Active not recruitingWashington University School of Medicine422021-08-242026-05-08
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy - Metastatic Uveal Melanoma
Phase 2TerminatedThomas Jefferson University132021-01-262025-07-15
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib - Non Small Cell Lung Cancer, KRAS Activating Mutation
Phase 2CompletedVerastem, Inc.902020-12-312024-01-12

Showing 20 of 28. Sign in to see all of them.

Conditions studied

Pancreatic Neoplasms (8)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Ovarian Neoplasms (5)  ·  Lung Neoplasms (4)  ·  Neoplasm Metastasis (3)  ·  Colorectal Neoplasms (2)  ·  Endometrial Neoplasms (2)  ·  Melanoma (2)  ·  Mesothelioma (2)  ·  Mesothelioma, Malignant (2)  ·  Stomach Neoplasms (2)  ·  Thyroid Neoplasms (2)  ·  Uterine Cervical Neoplasms (2)  ·  Adenocarcinoma of Lung (1)  ·  Adenoma (1)

Sponsors

Verastem, Inc. (10)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  Washington University School of Medicine (2)  ·  Emory University (1)  ·  Girish Dhall, MD (1)  ·  Institute of Cancer Research, United Kingdom (1)  ·  Lei Zheng (1)  ·  M.D. Anderson Cancer Center (1)  ·  Michael McHale (1)  ·  NHS Greater Glasgow and Clyde (1)  ·  National Cancer Institute (NCI) (1)  ·  Ryan H. Moy, MD, PhD (1)  ·  Thomas Jefferson University (1)  ·  University of Oklahoma (1)  ·  University of Utah (1)

Countries

United States (23)  ·  France (6)  ·  Spain (5)  ·  United Kingdom (5)  ·  Belgium (3)  ·  Italy (3)  ·  Australia (2)  ·  Canada (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Germany (1)  ·  Guam (1)  ·  New Zealand (1)  ·  Norway (1)  ·  Poland (1)

Top investigators

MD Verastem (5)  ·  Rachel Grisham, MD (3)  ·  Alan Ho, MD, PhD (1)  ·  Arsen Osipov, MD (1)  ·  Carl DeSelm, M.D., Ph.D. (1)  ·  Christian Ottensmeier (1)  ·  Christina Washington, MD (1)  ·  Christine Parseghian, MD (1)  ·  Conor E Steuer (1)  ·  David E Gerber, M.D. (1)  ·  Dean Fennell (1)  ·  Girish Dhall, MD (1)  ·  Hagop Youssoufian (1)  ·  Howard Colman, MD, PhD (1)  ·  Jeff Evans (1)

Results publications

PMID 37598000, PMID 26586415, PMID 27025608, PMID 30785827, PMID 32463741, PMID 33048619, PMID 34663687, PMID 35133871, PMID 35138919, PMID 35285277, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38493021, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40644648, PMID 40865033, PMID 41066729, PMID 42814800

NIH funding

2015 (1), P01CA257906 (1), P30CA138292 (1), R01CA248917 (1), U10CA180820 (1), U24CA196172 (1)